Revenue: As of FY2025 Q4, the actual value is USD 23.7 M, beating the estimate of USD 23.1 M.<h4>Preliminary Fourth Quarter 2025 Financial Highlights</h4>Harvard Bioscience, Inc. expects to report preliminary fourth quarter revenue of $23.7 million, which is above the midpoint of its guidance range of $22.5 million to $24.5 million . Gross Margin is expected to be 60%, reaching the high end of the 58% to 60% guidance range, attributed to an improved mix towards higher margin product lines and benefits from prior cost reductions . Adjusted EBITDA is anticipated to be $3.8 million, marking a 27% year-over-year growth, driven by cost reduction, improved expense management, and solid execution .<h4>Outlook for 2026</h4>For 2026, Harvard Bioscience, Inc. expects year-over-year revenue growth . The company also anticipates mid-to high-single-digit adjusted EBITDA growth for 2026 .

Harvard Bioscience | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 23.7 M